GH Research PLC (GHRS)
GHRS Stock Price Chart
Explore GH Research PLC interactive price chart. Choose custom timeframes to analyze GHRS price movements and trends.
GHRS Company Profile
Discover essential business fundamentals and corporate details for GH Research PLC (GHRS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Jun 2021
Employees
50.00
Website
https://www.ghres.comCEO
Velichka Valcheva
Description
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
GHRS Financial Timeline
Browse a chronological timeline of GH Research PLC corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.23.
Earnings released on 7 Aug 2025
EPS came in at -$0.15 surpassing the estimated -$0.22 by +31.82%.
Earnings released on 8 May 2025
EPS came in at -$0.19 surpassing the estimated -$0.61 by +68.85%.
Earnings released on 27 Feb 2025
EPS came in at -$0.17 surpassing the estimated -$0.23 by +26.09%.
Earnings released on 14 Nov 2024
EPS came in at -$0.23 surpassing the estimated -$0.25 by +8.00%.
Earnings released on 3 Sept 2024
EPS came in at -$0.20 surpassing the estimated -$0.24 by +16.67%.
Earnings released on 3 May 2024
EPS came in at -$0.15 surpassing the estimated -$0.22 by +31.82%, while revenue for the quarter reached $80.00K .
Earnings released on 29 Feb 2024
EPS came in at -$0.21 falling short of the estimated -$0.20 by -5.00%.
Earnings released on 9 Nov 2023
EPS came in at -$0.11 surpassing the estimated -$0.20 by +45.00%.
Earnings released on 23 Aug 2023
EPS came in at -$0.15 surpassing the estimated -$0.32 by +53.13%.
Earnings released on 11 May 2023
EPS came in at -$0.21 surpassing the estimated -$0.24 by +12.50%.
Earnings released on 2 Mar 2023
EPS came in at -$0.32 falling short of the estimated -$0.18 by -77.78%.
Earnings released on 10 Nov 2022
EPS came in at -$0.01 surpassing the estimated -$0.17 by +94.12%.
Earnings released on 23 Aug 2022
EPS came in at -$0.12 surpassing the estimated -$0.17 by +29.41%.
Earnings released on 18 May 2022
EPS came in at -$0.11 surpassing the estimated -$0.16 by +31.25%.
Earnings released on 28 Mar 2022
EPS came in at -$0.09 surpassing the estimated -$0.11 by +18.18%.
Earnings released on 6 Dec 2021
EPS came in at -$0.04 surpassing the estimated -$0.09 by +55.56%.
Earnings released on 23 Sept 2021
EPS came in at -$0.05 surpassing the estimated -$0.08 by +37.50%.
Earnings released on 28 Jun 2021
EPS came in at -$0.01 .
Earnings released on 31 Mar 2021
EPS came in at -$0.02 .
Earnings released on 30 Sept 2020
EPS came in at -$0.00 .
GHRS Stock Performance
Access detailed GHRS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.